JP2013503205A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503205A5 JP2013503205A5 JP2012527108A JP2012527108A JP2013503205A5 JP 2013503205 A5 JP2013503205 A5 JP 2013503205A5 JP 2012527108 A JP2012527108 A JP 2012527108A JP 2012527108 A JP2012527108 A JP 2012527108A JP 2013503205 A5 JP2013503205 A5 JP 2013503205A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- composition
- polypeptide
- fused
- transplant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000037240 fusion proteins Human genes 0.000 claims 9
- 108020001507 fusion proteins Proteins 0.000 claims 9
- 102000004965 antibodies Human genes 0.000 claims 7
- 108090001123 antibodies Proteins 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 206010018651 Graft versus host disease Diseases 0.000 claims 6
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 6
- 230000037361 pathway Effects 0.000 claims 6
- 210000000056 organs Anatomy 0.000 claims 5
- 210000001519 tissues Anatomy 0.000 claims 5
- 230000002708 enhancing Effects 0.000 claims 4
- 102000018358 Immunoglobulins Human genes 0.000 claims 2
- 108060003951 Immunoglobulins Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000001185 Bone Marrow Anatomy 0.000 claims 1
- 229960003957 Dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N Fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 101700086956 IFNG Proteins 0.000 claims 1
- 102100016020 IFNG Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 210000000447 Th1 Cells Anatomy 0.000 claims 1
- 210000000068 Th17 Cells Anatomy 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 230000000735 allogeneic Effects 0.000 claims 1
- 229960004729 colecalciferol Drugs 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 1
- 229940021056 vitamin D3 Drugs 0.000 claims 1
- 235000005282 vitamin D3 Nutrition 0.000 claims 1
- 239000011647 vitamin D3 Substances 0.000 claims 1
Claims (13)
- 被験体における移植組織または移植器官の拒絶反応を阻害または軽減するための組成物であって、
前記組成物は、第2のポリペプチドに融合した、または第2のポリペプチドに融合したリンカーペプチドに融合した、配列番号63または配列番号64のIgVドメインを含むB7−H4ポリペプチドを含む融合タンパク質を含み、
前記融合タンパク質は、前記被験体においてTh1経路またはTh17経路に対するTregの抑制効果を増強し、前記被験体における移植された組織または器官の拒絶反応を軽減するのに有効な量で存在する、
組成物。 - 被験体における移植組織または移植器官の拒絶反応を阻害または軽減するための組成物であって、
前記組成物は、第2のポリペプチドに融合した、または第2のポリペプチドに融合したリンカーペプチドに融合した、配列番号63または配列番号64のIgVドメインを含むB7−H4ポリペプチドを含む融合タンパク質を含み、
前記第2のポリペプチドは、ヒトIgG1免疫グロブリンのヒンジ領域、CH2領域およびCH3領域を含み、
前記融合タンパク質は、前記被験体においてTh1経路またはTh17経路に対するTregの抑制効果を増強し、前記被験体における移植された組織または器官の拒絶反応を軽減するのに有効な量で存在する、
組成物。 - 前記融合タンパク質が、前記被験体において前記Th17経路に対するTregの抑制効果を増強するのに有効な量で存在する、請求項1または2に記載の組成物。
- 前記被験体においてTh17細胞の数を低減させる、請求項1〜3のいずれか一項に記載の組成物。
- 前記被験体においてTh1細胞の数を低減させる、請求項1〜4のいずれか一項に記載の組成物。
- 前記被験体においてIL−17のレベルを低減させる、請求項1〜5のいずれか一項に記載の組成物。
- 第2の治療剤をさらに含む、請求項1〜6のいずれか一項に記載の組成物。
- 前記第2の治療剤が、グルココルチコイド、フルチカゾン、サルメテロール(salmeteroal);IL−12に対する抗体、IL−6に対する抗体、IFN−γに対する抗体、IL−23に対する抗体、IL−22に対する抗体、IL−21に対する抗体、およびIL−4に対する抗体;ビタミンD3;CTLA−4−Ig、ベラタセプト;デキサメタゾン、ならびにその組合せからなる群から選択される、請求項7に記載の組成物。
- 前記移植が、同種異系移植である、請求項1〜8のいずれか一項に記載の組成物。
- 前記移植が、皮膚移植、組織移植、臓器移植、または骨髄移植である、請求項1〜9のいずれか一項に記載の組成物。
- 被験体における移植片対宿主病(GVHD)の1または複数の症状を処置するための組成物であって、
前記組成物は、第2のポリペプチドに融合した、または第2のポリペプチドに融合したリンカーペプチドに融合した、配列番号63または配列番号64のIgVドメインを含むB7−H4ポリペプチドを含む融合タンパク質を含み、
前記融合タンパク質は、前記被験体においてGVHDの1または複数の症状を緩和するのに有効な量で存在する、
組成物。 - 被験体における移植片対宿主病(GVHD)の1または複数の症状を処置するための組成物であって、
前記組成物は、第2のポリペプチドに融合した、または第2のポリペプチドに融合したリンカーペプチドに融合した、配列番号63または配列番号64のIgVドメインを含むB7−H4ポリペプチドを含む融合タンパク質を含み、
前記第2のポリペプチドは、ヒトIgG1免疫グロブリンのヒンジ領域、CH2領域およびCH3領域を含み、
前記融合タンパク質は、前記被験体においてGVHDの1または複数の症状を緩和するのに有効な量で存在する、
組成物。 - 前記Th17経路に対するTregの抑制効果を増強することによって、被験体における移植拒絶反応を阻害する方法で使用するための、請求項1〜12のいずれか一項に記載の組成物。
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23860509P | 2009-08-31 | 2009-08-31 | |
US61/238,605 | 2009-08-31 | ||
US25493009P | 2009-10-26 | 2009-10-26 | |
US61/254,930 | 2009-10-26 | ||
US26685409P | 2009-12-04 | 2009-12-04 | |
US61/266,854 | 2009-12-04 | ||
US28653709P | 2009-12-15 | 2009-12-15 | |
US61/286,537 | 2009-12-15 | ||
US37836110P | 2010-08-30 | 2010-08-30 | |
US61/378,361 | 2010-08-30 | ||
PCT/US2010/047384 WO2011026132A2 (en) | 2009-08-31 | 2010-08-31 | Methods and compositions for the inhibition of transplant rejection |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013503205A JP2013503205A (ja) | 2013-01-31 |
JP2013503205A5 true JP2013503205A5 (ja) | 2013-10-17 |
Family
ID=42990231
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012527101A Pending JP2013503204A (ja) | 2009-08-31 | 2010-08-31 | B7−h4融合タンパク質およびその使用方法 |
JP2012527108A Pending JP2013503205A (ja) | 2009-08-31 | 2010-08-31 | 移植拒絶反応を阻害するための方法および組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012527101A Pending JP2013503204A (ja) | 2009-08-31 | 2010-08-31 | B7−h4融合タンパク質およびその使用方法 |
Country Status (8)
Country | Link |
---|---|
US (4) | US9005616B2 (ja) |
EP (2) | EP2473523A2 (ja) |
JP (2) | JP2013503204A (ja) |
CN (2) | CN102741279A (ja) |
AU (2) | AU2010286361A1 (ja) |
CA (2) | CA2772199A1 (ja) |
IN (2) | IN2012DN02753A (ja) |
WO (2) | WO2011026132A2 (ja) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002010187A1 (en) | 2000-07-27 | 2002-02-07 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
JP2011502954A (ja) * | 2006-12-27 | 2011-01-27 | ザ ジョンズ ホプキンス ユニバーシティー | 免疫応答を刺激する組成物および方法 |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
EP2473523A2 (en) | 2009-08-31 | 2012-07-11 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
WO2012021512A2 (en) | 2010-08-10 | 2012-02-16 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
WO2012078673A1 (en) * | 2010-12-06 | 2012-06-14 | Confluence Life Sciences, Inc. | Substituted pyridine urea compounds |
WO2012145568A1 (en) * | 2011-04-21 | 2012-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Antibodies to human b7x for treatment of metastatic cancer |
AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
MX2015007846A (es) | 2012-12-19 | 2016-04-28 | Amplimmune Inc | Anticuerpos anti-b7-h4 humana y sus usos. |
GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
EP2997373A1 (en) * | 2013-05-17 | 2016-03-23 | MedImmune, LLC | Receptors for b7-h4 |
WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
WO2015016718A1 (en) | 2013-08-02 | 2015-02-05 | Bionovion Holding B.V. | Combining cd27 agonists and immune checkpoint inhibition for immune stimulation |
US10370776B2 (en) * | 2013-09-25 | 2019-08-06 | Idea Orchard, Llc | Antibody like protein |
EP3076975A4 (en) * | 2013-12-02 | 2017-05-03 | Pharmacyclics, LLC | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
US10689432B2 (en) * | 2013-12-18 | 2020-06-23 | Albert Einstein College Of Medicine | B7X and its derivatives for treating and preventing cardiovascular disease |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
AU2015233084B2 (en) | 2014-02-21 | 2020-12-17 | Anokion Sa | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
CA2942384C (en) | 2014-03-12 | 2024-01-23 | Icahn School Of Medicine At Mount Sinai | Method for identifying kidney allograft recipients at risk for chronic injury |
US9730988B2 (en) * | 2014-04-10 | 2017-08-15 | University Of Iowa Research Foundation | Parasitic biological agents for treatment and prevention of graft versus host disease |
ES2897004T3 (es) * | 2014-06-26 | 2022-02-28 | Icahn School Med Mount Sinai | Métodos para diagnosticar el riesgo de fibrosis y rechazo de aloinjerto renal |
ES2850281T3 (es) | 2014-06-26 | 2021-08-26 | Icahn School Med Mount Sinai | Método para diagnosticar el rechazo agudo subclínico y clínico mediante el análisis de conjuntos de genes predictivos, un agente terapéutico para usar en el tratamiento y kits para determinar la expresión |
US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
EP4005386A1 (en) | 2015-05-06 | 2022-06-01 | SNIPR Technologies Limited | Altering microbial populations & modifying microbiota |
ES2957882T3 (es) | 2015-09-04 | 2024-01-29 | Univ Yale | Nanocomposiciones de ácidos biliares poliméricos dirigidas al páncreas y al colon |
AU2016323769B2 (en) * | 2015-09-17 | 2022-05-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Compositions comprising pregnancy specific glycoproteins and methods of use thereof |
JP2018532810A (ja) | 2015-11-07 | 2018-11-08 | マルチビア インコーポレイテッド | がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物 |
PL3429618T3 (pl) | 2016-03-16 | 2024-07-01 | Amal Therapeutics Sa | Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie |
KR20190057345A (ko) | 2016-09-21 | 2019-05-28 | 아말 테라퓨틱스 에스에이 | 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체 |
EP4360714A3 (en) | 2016-09-21 | 2024-07-24 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
AU2017330346A1 (en) | 2016-09-21 | 2019-02-21 | Nextcure, Inc. | Antibodies for Siglec-15 and methods of use thereof |
US11395838B2 (en) | 2016-09-27 | 2022-07-26 | Board Of Regents, The University Of Texas System | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome |
CA3040458A1 (en) | 2016-10-12 | 2018-04-19 | Board Of Regents, The University Of Texas System | Methods and compositions for tusc2 immunotherapy |
WO2018099539A1 (en) | 2016-11-29 | 2018-06-07 | Horst Lindhofer | Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof |
JP2020510624A (ja) | 2016-12-12 | 2020-04-09 | マルチビア インコーポレイテッド | がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物 |
WO2018176144A1 (en) * | 2017-03-29 | 2018-10-04 | Sunnybrook Research Institute | Engineered t-cell modulating molecules and methods of using same |
KR20190137911A (ko) | 2017-04-21 | 2019-12-11 | 신라젠(주) | 항암 백시니아 바이러스와 관문 저해제 병용 요법 |
WO2018219956A1 (en) | 2017-05-29 | 2018-12-06 | Gamamabs Pharma | Cancer-associated immunosuppression inhibitor |
EP3638296A1 (en) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
WO2018237003A1 (en) * | 2017-06-23 | 2018-12-27 | Sanford Health | METHODS FOR PRODUCING INDUCED REGULATORY T CELLS |
CN111094352A (zh) | 2017-08-25 | 2020-05-01 | 戊瑞治疗有限公司 | B7-h4抗体及其使用方法 |
AU2018338786A1 (en) * | 2017-09-29 | 2020-04-16 | Nantcell, Inc. | Antigenic proteins and methods therefor |
DK3743447T3 (da) | 2018-01-23 | 2024-05-27 | Nextcure Inc | B7-H4-antistoffer og fremgangsmåder til anvendelse deraf |
CN108236719A (zh) * | 2018-01-29 | 2018-07-03 | 中山大学附属第三医院(中山大学肝脏病医院) | B7-h4融合蛋白在制备治疗系统性红斑狼疮药物中的用途 |
US12090142B2 (en) | 2018-02-22 | 2024-09-17 | Board Of Regents, The University Of Texas System | Combination therapy for the treatment of cancer |
WO2019169229A1 (en) | 2018-03-01 | 2019-09-06 | Nextcure, Inc. | Klrg1 binding compositions and methods of use thereof |
AU2019228600A1 (en) | 2018-03-02 | 2020-09-24 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
EP3773685A1 (en) | 2018-03-25 | 2021-02-17 | SNIPR Biome ApS. | Treating & preventing microbial infections |
CA3095198A1 (en) | 2018-04-16 | 2019-10-24 | Icahn School Of Medicine At Mount Sinai | Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood |
CN109439626B (zh) * | 2018-11-09 | 2022-10-14 | 复旦大学附属中山医院 | 一种有助于体外获得Th22细胞的组合物及其用途 |
CA3120576A1 (en) | 2018-11-26 | 2020-06-04 | Massachusetts Institute Of Technology | Compositions and methods for immune tolerance |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
AU2021285044A1 (en) | 2020-06-03 | 2022-12-08 | Institute For Research In Biomedicine | Combination of an ATP-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof |
CN116600789A (zh) | 2020-06-19 | 2023-08-15 | 耶鲁大学 | 用于诱导耐受性的聚合胆汁酸酯纳米颗粒 |
EP4178611A1 (en) | 2020-07-07 | 2023-05-17 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
CN114426974B (zh) * | 2020-10-29 | 2023-11-21 | 洛阳普泰生物技术有限公司 | 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段 |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1339281A (en) | 1920-01-26 | 1920-05-04 | Stearns | Upholstery-fold |
GB1268212A (en) | 1968-04-19 | 1972-03-22 | Zaidan Hojin Biseibutsu | Tripeptide derivatives |
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
US4272398A (en) | 1978-08-17 | 1981-06-09 | The United States Of America As Represented By The Secretary Of Agriculture | Microencapsulation process |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5155020A (en) | 1989-03-08 | 1992-10-13 | Health Research Inc. | Recombinant poxvirus host range selection system |
CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US6808901B1 (en) | 1984-09-03 | 2004-10-26 | Celltech R&D Limited | Production of chimeric antibodies |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
WO1988001213A1 (en) | 1986-08-18 | 1988-02-25 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
US4853871A (en) | 1987-04-06 | 1989-08-01 | Genex Corporation | Computer-based method for designing stablized proteins |
US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
US4861627A (en) | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
US5750666A (en) | 1988-05-26 | 1998-05-12 | Competitve Technologies, Inc. | Polynucleotide phosphorodithioate compounds |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
US5175099A (en) | 1989-05-17 | 1992-12-29 | Research Corporation Technologies, Inc. | Retrovirus-mediated secretion of recombinant products |
US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5204243A (en) | 1990-02-14 | 1993-04-20 | Health Research Incorporated | Recombinant poxvirus internal cores |
US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992005186A1 (en) | 1990-09-20 | 1992-04-02 | Gilead Sciences | Modified internucleoside linkages |
US5296347A (en) | 1991-02-08 | 1994-03-22 | Ciba Corning Diagnostics Corp. | Bridge immunoassay |
CA2082951C (en) | 1991-03-15 | 1999-12-21 | Robert M. Platz | Pulmonary administration of granulocyte colony stimulating factor |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
WO1993001222A1 (en) | 1991-07-03 | 1993-01-21 | Kanebo, Ltd. | Thermoplastic polyurethane elastomer, method and device for manufacture thereof, and elastic fiber made therefrom |
US5202332A (en) | 1991-08-07 | 1993-04-13 | American Home Products Corporation | Rapamycin analog as immunosuppressant |
US5162333A (en) | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993019763A1 (en) | 1992-03-30 | 1993-10-14 | American Home Products Corporation | Rapamycin formulation for iv injection |
US5434260A (en) | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
US5489680A (en) | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
US5387680A (en) | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
WO1995007707A1 (en) | 1993-09-14 | 1995-03-23 | Cytel Corporation | Alteration of immune response using pan dr-binding peptides |
US5385908A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
WO1995016691A1 (en) | 1993-12-17 | 1995-06-22 | Sandoz Ltd. | Rapamycin derivatives useful as immunosuppressants |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
US5362735A (en) | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
NZ322174A (en) | 1995-11-10 | 1999-02-25 | Elan Corp Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
WO1999063088A2 (en) | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Membrane-bound proteins and nucleic acids encoding the same |
AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
US6982323B1 (en) | 1997-12-23 | 2006-01-03 | Alexion Pharmaceuticals, Inc. | Chimeric proteins for diagnosis and treatment of diabetes |
CA2331149A1 (en) | 1998-06-04 | 1999-12-09 | The University Of Queensland | Phenotype modifying genetic sequences |
GB9814640D0 (en) | 1998-07-06 | 1998-09-02 | Fujisawa Pharmaceutical Co | New use |
US6015809A (en) | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
ATE413466T1 (de) | 1998-09-02 | 2008-11-15 | Diadexus Inc | Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen |
US6962980B2 (en) | 1999-09-24 | 2005-11-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6468546B1 (en) | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
US20030187196A1 (en) | 1998-12-30 | 2003-10-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
CA2377513A1 (en) | 1999-06-25 | 2001-01-04 | Universitat Zurich | Hetero-associating coiled-coil peptides |
WO2001001137A1 (en) | 1999-06-30 | 2001-01-04 | Children's Medical Center Corporation | Fusion protein and uses thereof |
DE19937656A1 (de) | 1999-08-13 | 2001-02-15 | Aventis Behring Gmbh | Verwendung von Antithrombin III zur Prophylaxe und Therapie von Erkrankungen |
JP2004502417A (ja) | 2000-06-30 | 2004-01-29 | アムジェン インコーポレーテッド | B7様分子およびその使用 |
WO2002002587A1 (en) * | 2000-06-30 | 2002-01-10 | Human Genome Sciences, Inc. | B7-like polynucleotides, polypeptides, and antibodies |
US6537968B1 (en) | 2000-07-24 | 2003-03-25 | Alphamed Pharmaceuticals Corp | Treatment of lupus erythematosus |
WO2002010187A1 (en) * | 2000-07-27 | 2002-02-07 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
US6828112B2 (en) | 2001-01-04 | 2004-12-07 | Myriad Genetics, Inc. | Method of detecting protein-protein interactions |
EP1354035B1 (en) | 2001-01-26 | 2016-08-24 | Commonwealth Scientific and Industrial Research Organisation | Methods and means for producing efficient silencing construct using recombinational cloning |
CA2438513C (en) | 2001-02-19 | 2013-08-13 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Modified anti-egfr antibodies with reduced immunogenicity |
WO2004000221A2 (en) | 2002-06-20 | 2003-12-31 | The Regents Of The University Of California | Compositions and methods for modulating lymphocyte activity |
AU2003258714A1 (en) | 2002-09-06 | 2004-03-29 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
US7449300B2 (en) | 2002-11-21 | 2008-11-11 | Mayo Foundation For Medical Education And Research | Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells |
US7534423B2 (en) | 2003-03-28 | 2009-05-19 | Faron Pharmaceuticals Oy | Method for inducing an elevated level of adenosine in an individual |
US20050163772A1 (en) | 2003-06-16 | 2005-07-28 | University Of Washington | B7S1: an immune modulator |
JP5130044B2 (ja) | 2004-08-03 | 2013-01-30 | イナート・ファルマ | 4ig−b7−h3およびその対応するnk細胞受容体を標的化する治療および診断方法ならびに組成物 |
WO2006101487A1 (en) | 2005-03-18 | 2006-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Production and therapeutic uses of th1-like regulatory t cells |
EP3214095B1 (en) | 2005-05-12 | 2019-12-11 | ZymoGenetics, Inc. | Compositions and methods for modulating immune responses |
US8652465B2 (en) | 2005-06-08 | 2014-02-18 | Emory University | Methods and compositions for the treatment of persistent infections |
US20090130067A1 (en) * | 2005-09-23 | 2009-05-21 | Dirk Buscher | Cell Population Having Immunoregulatory Activity, Method for Isolation and Uses |
KR20080090412A (ko) | 2005-12-08 | 2008-10-08 | 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 | 생체내 세포 표면 엔지니어링 |
US8241621B2 (en) | 2006-12-18 | 2012-08-14 | Medistem Laboratories | Stem cell mediated treg activation/expansion for therapeutic immune modulation |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
JP2011502954A (ja) | 2006-12-27 | 2011-01-27 | ザ ジョンズ ホプキンス ユニバーシティー | 免疫応答を刺激する組成物および方法 |
US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
WO2008147482A2 (en) | 2007-02-13 | 2008-12-04 | Northeastern University | Methods and compositions for improving immune responses |
US20100203035A1 (en) | 2007-02-14 | 2010-08-12 | Kwon Eugene D | B7-h3 in cancer |
US20110020269A1 (en) * | 2007-05-08 | 2011-01-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for modifying t cell immune responses and inflammation |
PT2162011E (pt) | 2007-07-02 | 2011-06-16 | Sime Darby Malaysia Berhad | Mistura de gorduras vegetais e produtos comestíveis que contêm esta mistura de gorduras |
US20090124573A1 (en) | 2007-11-09 | 2009-05-14 | Sarkis Mazmanian | Immunomodulating compounds and related compositions and methods |
AU2009204441B2 (en) * | 2008-01-09 | 2015-03-05 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of ocular inflammatory disorders |
EP2473523A2 (en) | 2009-08-31 | 2012-07-11 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
JP2012118516A (ja) | 2010-11-11 | 2012-06-21 | Konica Minolta Business Technologies Inc | ホログラム画像形成方法、静電荷像現像用トナーおよびホログラム画像形成装置 |
EP2997373A1 (en) * | 2013-05-17 | 2016-03-23 | MedImmune, LLC | Receptors for b7-h4 |
-
2010
- 2010-08-31 EP EP10752959A patent/EP2473523A2/en not_active Withdrawn
- 2010-08-31 US US13/392,399 patent/US9005616B2/en not_active Expired - Fee Related
- 2010-08-31 EP EP10748218A patent/EP2473521A2/en not_active Withdrawn
- 2010-08-31 AU AU2010286361A patent/AU2010286361A1/en not_active Abandoned
- 2010-08-31 WO PCT/US2010/047384 patent/WO2011026132A2/en active Application Filing
- 2010-08-31 CN CN2010800488674A patent/CN102741279A/zh active Pending
- 2010-08-31 CN CN2010800488477A patent/CN102666581A/zh active Pending
- 2010-08-31 CA CA2772199A patent/CA2772199A1/en not_active Abandoned
- 2010-08-31 JP JP2012527101A patent/JP2013503204A/ja active Pending
- 2010-08-31 JP JP2012527108A patent/JP2013503205A/ja active Pending
- 2010-08-31 IN IN2753DEN2012 patent/IN2012DN02753A/en unknown
- 2010-08-31 WO PCT/US2010/047366 patent/WO2011026122A2/en active Application Filing
- 2010-08-31 AU AU2010286351A patent/AU2010286351A1/en not_active Abandoned
- 2010-08-31 US US13/392,811 patent/US9011853B2/en active Active
- 2010-08-31 CA CA2772204A patent/CA2772204A1/en not_active Abandoned
- 2010-08-31 IN IN2764DEN2012 patent/IN2012DN02764A/en unknown
-
2015
- 2015-04-06 US US14/679,505 patent/US20160039906A1/en not_active Abandoned
- 2015-04-06 US US14/679,497 patent/US9957312B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013503205A5 (ja) | ||
NL301196I2 (nl) | inebilizumab | |
JP2020511672A5 (ja) | ||
BRPI0510881A (pt) | anticorpos contra interleucina-13 humana e usos dos mesmos | |
EP2352523A4 (en) | IMPROVED ANTI-CD19 ANTIBODIES | |
PH12016500859B1 (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
MX2012005864A (es) | Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas. | |
MX2012001882A (es) | Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso. | |
EA201000424A1 (ru) | Антитела к il-23 | |
WO2008109155A3 (en) | Compositions and methods for treatment of cervical cancer | |
WO2010021874A3 (en) | Engineered anti-il-13 antibodies, compositions, methods and uses | |
NO20063926L (no) | N-terminale monopegylerte humane veksthormonkonjugater, fremgangsmater for fremstilling og anvendelse av disse | |
MY144906A (en) | Human antibodies against il13 and therapeutic uses | |
UA116614C2 (uk) | Антитіло до фактора d і його застосування | |
EA201000644A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
EA200870274A1 (ru) | ПЕПТИДЫ, БЛОКИРУЮЩИЕ СВЯЗЫВАНИЕ IgG C FcRn | |
WO2010055366A3 (en) | Anti-human il-21 monoclonal antibodies | |
MX338421B (es) | Anticuerpos fosfoespecificos que reconocen la proteina tau. | |
WO2006089133A8 (en) | Anti-cd19 antibodies and uses in oncology | |
WO2009048538A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
WO2013013025A3 (en) | Anti-cxcr4 antibodies and methods of use | |
WO2009048539A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
WO2020076969A3 (en) | Anti-lap antibody variants and uses thereof | |
Roh et al. | Depletion of Foxp3+ regulatory T cells promotes profibrogenic milieu of cholestasis-induced liver injury | |
MX2011012622A (es) | Proteina de enlace de il-13. |